Primrose Bio's recent investment from 1315 Capital marks a pivotal moment in biomanufacturing innovation. With this substantial financial backing, Primrose is well-positioned to advance its cutting-edge technologies, such as Prima RNApols™, which significantly enhances mRNA production, and Pfenex Expression Technology®, which offers superior yields in drug manufacturing. This partnership not only underscores the value of Primrose’s platforms but also highlights a growing recognition of the need for more efficient and scalable production methods in the pharmaceutical industry. The strategic support from 1315 Capital will undoubtedly propel Primrose Bio to new heights, reinforcing its role as a leader in biomanufacturing solutions.